TP53 and B-cell chronic lymphocytic leukemia: We and other groups of investigators have previously demonstrated the potential therapeutic efficacy of Nutlin-3, a small molecule non-genotoxic activator of the p53 pathway, in p53wild-type B-CLL cells [21,22].